Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 8.64$. Average daily volumn in 3 months 1.03M. Market cap 8.90B

Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 10.13$. Total volume : 489.14k. Market state POST
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price

Previous Close10.07
Day Range10.10-10.32
Bid9.84 x 900
Ask10.18 x 900
Average Volume1.03M
Market Cap8.9B
52 Week Range5.71-13.34
Trailing P/E92.09
Foward P/E19.86
Dividend (Yield %)N/A
Ex-Dividend Date2021-06-03

Financial Details

According to Grifols, S.A.'s financial reports the company's revenue in 2021 were 4.93B an decrease(-20%) over the years 2020 revenue that were of 5.34B. In 2021 the company's total earnings were 182.8M while total earnings in 2020 were 618.55M(-70.55%).

Loading ...


Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumย–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoringย–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Market Cap:
Total Assets:
Total Cash:

News about "Grifols, S.A."

Grifols SA Pref (GRLSbn)

Source from : Investing - 5 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»

Grifols, S.A. (GIFOF)

Source from : Yahoo Finance - 4 years ago

Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing unidentified financial sources.See details»

GRLS.MC - | Stock Price & Latest News | Reuters

Source from : Reuters - 1 month ago

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes ...See details»

Grifols, S.A. (GRFS)

Source from : Yahoo Finance - 5 years ago

Spanish pharmaceutical company Grifols considers selling assets worth about 2 billion euros ($2.12 billion) to cut its debt, Cinco Dias reported on Wednesday, citing unidentified financial sources.See details»

Grifols SA PRF UNDATED EUR 0.05 GIFOF Stock Quote

Source from : Morningstar%2c Inc. - 27 days ago

No. GIFOF does not currently have a forward dividend yield. Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock ...See details»

Blood Plasma Products Market Growth Analysis Report 2023 to 2028 |CSL Ltd.,Creat Group Corporation,Grifols SA

Source from : MarketWatch - 8 days ago

Blood Plasma Products Market Size is projected to Reach Multimillion USD by 2028, In comparison to 2023, at unexpected CAGR during the forecast Period 2023-2028. Request To Sample of This Strategic ...See details»


US life science firms slow down hiring but still looking for Triangle talent, report says

Source from : WRAL TechWire - 20 hours ago

Nationwide, life science companies slowed down their efforts to identify, recruit, and hire talented workers in the fourth quarter of 2022, a new report shows.See details»

U.S. Intravenous Immunoglobulin Market Detailed In New Research Report 2023 | Biotest AG, Octapharma AG, Grifols S.A., Kedrion Biopharma, Inc.

Source from : Digital Journal - 1 month ago

This report studies the U.S. Intravenous Immunoglobulin Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief ...See details»

RFID Smart Cabinet Market Size 2023 With Presentation Outlook, Horizontal Viewpoint, Global View

Source from : MarketWatch - 2 days ago

In 2023] The Global RFID Smart Cabinet Market Size (125 Report Pages) is estimated to be worth USD million in 2021 and ...See details»

Fractiomaticยฎ Plus 2 Automated Blood Component Separator from GRIFOLS

Source from : News Medical - 2 years ago

Fractiomatic ยฎ Plus 2 is an automatic blood component separator with infrared detection sensor, automatic sealing heads, weighing of components and computerized data processing. Different ...See details»

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP

Source from : pharmaphorum - 3 month ago

Patients across the UK with chronic immune thrombocytopenia (ITP) now have another treatment option, after NICE backed use of Spanish drugmaker Grifols' Tavlesse for adults with the rare blood ...See details»

Ontario considered lifting ban on paid blood donation: e-mails

Source from : The Globe and Mail - 21 days ago

Grifols pays its donors ... concerned that private companies will prioritize profit over care. โ€œThereโ€™s a lot of people that are interested in health care because you can make a ton of ...See details»


Infectious Disease In-vitro Diagnostics Market Develop at a CAGR of 4.1% in the United States and Expected to Reach US$ 93.9 Bn by 2032

Source from : Medgadget - 14 days ago

The Global Infectious Disease In-Vitro Diagnostics Market was valued at US$ 58.7 Bn in 2021 and is expected to reach US$ 93.9 Bn by 2032, finds ...See details»

Leaders in Rush Yards Before and After Contact | Goodside Presented by Grifols Plasma Donation Centers

Source from : NFL - 3 month ago

Next, the pair look at what's a better situation, the Cardinals or Colts as they look ahead to each team's 2023 first-round draft pick. For the rest of the show, the duo pick which teams are the ...See details»